National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Talazoparib is indicated as monotherapy for the treatment of adult patients with germline BRCA1/2 mutations, who have HER2-negative locally advanced or metastatic breast cancer.

NCPE Assessment Process Complete
Rapid review commissioned 19/08/2019
Rapid review completed 03/09/2019
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of talazoparib compared with the current standard of care.